Plandai Biotechnology Inc (OTCMKTS:PLPL) disclosed that the revenue in the first nine months of FY2015 came at $64,024 versus $250,859 in the comparable period, a year ago. This revenue figure included the sales of timber from the tea estate operations in South Africa. During the same period, the cost of sales was $583,506 against $483,675 in the same period in FY2014. More recently, the company stated that USN is innovating new products using Phytofare® complex.
In unrelated news, Plandai revealed that Azochem Laboratories placed another purchase order for Phytofare® ingredient. Mr. Callum Cottrell-Duffield stated that as part of three year contract with USN, under which the company will supply complex to USN manufacturers, the product can be found on shelves across different parts of world in coming period. Azochem is a USN contract manufacturer and it is based in South Africa. The VP of sales & marketing division added that they fulfill all contractual requirements to meet the needs of USN contractors quickly and competently.
In early morning trade on Tuesday, the stock price of Plandai is trading flat at $0.140. The market cap of the company stands at $22.47 million.
MABVAX THERAPEUTICS (OTCMKTS:MBVX) Presented At World Molecular Imaging Congress
The leading biotech firm, MABVAX THERAPEUTICS (OTCMKTS:MBVX) disclosed that its lead antibody, known as HuMab 5B1, was highlighted in different presentations at the renowned World Molecular Imaging Congress held last week. The research team presented data on the use of HuMab 5B1 as a PET imaging and radio immunotherapy agent for cure of pancreatic cancer. The participants were Jacob Houghton, Dalya Abdel-Atti and Jan-Philip Meyer, Ph.D.
Immunomedics, Inc. (NASDAQ:IMMU) To Take Part In Wells Fargo Securities Healthcare Conference
Immunomedics, Inc. (NASDAQ:IMMU) disclosed that its expert team will participate in a Hematology and Oncology Panel at forthcoming Wells Fargo Securities Healthcare Conference scheduled this Wednesday.